A Case Report of a Severely Aggressive Uterine Sarcoma at an Unusual Age

Document Type: Case Report

Authors

1 Assistant Professor of Obstetrics & Gynecology, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

2 Resident of Obstetrics & Gynecology, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran

Abstract

Uterine sarcomas are very unique tumors with mesodermial origin and accounting for 2-6% of uterine cancers. In general, uterine sarcomas are the most malignant tumors of the uterus. Their usual histologic types are endometrial estromal sarcoma, lieomyosarcoma and malignant mixed mullerian tumor or carcinosarcoma
In this case report, a 19 year old woman with chief complaint of abnormal uterine bleeding from 1 year ago is presented. The patient had 3 times curettage in this period and due to the last pathology report that was suspicious for uterine sarcoma referred to Afzali Poor Hospital. In the last sonography, a huge pelvic mass was reported with hydronephrosis and dilated left ureter. Furthermore, in the last CT scan a suspicious mass in favor of leiomyoma was reported too. In laparotomy surgery due to frozen section report of fibro sarcoma, hysterectomy and bilateral salpigo oophorectomy was done. In final pathology, endometrial stromal sarcoma was reported.  Endometrial stromal sarcoma accounts for 15% of uterine sarcomas usually seen in perimenopausal period. The usual symptom of this tumor is abnormal uterine bleeding. Some of these patients are asymptomatic. The main therapy of these patients is total hysterectomy and bilateral salpingo oophorecomy.

  1. Nordal RR, Thoresen SO. Uterine sarcomas in Norway 1956-1992: incidence, survival and mortality. Eur J Cancer 1997; 33(6): 907-11.
  2. Clement PB, YoungRH. Mesenchymal and mixed epithelial –mesenchymal tumors of the uterin corpus and cervix. In: Clement PB, Young RH, eds., atlas of gynecologic surgical pathologoy. Philadelphia, PA: saunders, 2000; PP 177-210.
  3. Brooks SE, ZhanM, CoteT, Baquet CR. Surveillance, epidemiology, end results analysis of 2677 cases of uterin sarcoma 1989-1999.Gynecol Oncol 2004; 93(1): 204-8.
  4. Lee CH, Marino-Enriquez A, Ou W, Zhu M, Ali RH, Chiang S, et al. The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. Am J Surg Pathol 2012; 36(5): 641-53.
  5. Kempson RL, Bari W. uterinsarcomas: classification, diagnosis and prognosis. Hum Pathol 1970; 1: 331-49
  6. Yu CL, Tucker MA, Abramson DH, Furukawa K, Seddon JM, Stovall M, et al. Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst 2009; 101(8): 581-91.
  7. Koivisto-Korander R, Butzow R, Koivisto AM, Leminen A. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001. Gynecol Oncol 2008; 111(1): 74-81.
  8. Rauh-Hain JA, del Carmen MG. Endometrial stromal sarcoma: a systematic review. Obstet Gynecol 2013; 122(3): 676-83.
  9. Group ESNW. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl 7): vii 92-99.
  10. D'Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol 2010; 116: 113-39.
  11. Signorelli M, Fruscio R, Dell'Anna T, Buda A, Giuliani D, Ceppi L, et al. Lymphadenectomy in uterine low-grade endometrial stromal sarcoma: an analysis of 19 cases and a literature review. Int J Gynecol Cancer 2010; 20(8): 1363-6.
  12. Leung F, Terzibachian JJ, Gay C, Chung Fat B, Aouar Z, Lassabe C, et al. [Hysterectomies performed for presumed leiomyomas: should the fear of leiomyosarcoma make us apprehend non laparotomic surgical routes?]. Gynecol Obstet Fertil 2009; 37(2): 109-14.
  13. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 2004; 93(1): 204-8.
  14. Barney B, Tward JD, Skidmore T, Gaffney DK. Does radiotherapy or lymphadenectomy improve survival in endometrial stromal sarcoma? Int J Gynecol Cancer 2009; 19(7): 1232-8.
  15. Shah JP, Bryant CS, Kumar S, Ali-Fehmi R, Malon JM, Morris RT, et al. Lymphadenectomy and ovarian preservation in low-grade endometrial stromal sarcoma. Obstet Gynecol 2008; 112(5): 1102-8.
  16. Amant F, Coosemans A, Debiec-Rychter M, Timmerman D, Vergote I et al. Clinical management of uterine sarcomas. Lancet Oncol 2009; 10(12): 1188-98.
  17. Reichardt P. The treatment of uterine sarcomas. Ann Oncol 2012; 23 (Suppl 10): x 151-157.
  18. Thanopoulou E, Judson I. Hormonal therapy in gynecological sarcomas. Expert Rev Anticancer Ther 2012; 12(7): 885-94.
  19. Pink D, Lindner T, Mrozek A, Kvetzschmar A, thuss-Patience PC, Dorken B, et al. Harm or benefit of hormonal treatment in metastic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol 2006; 101(3): 464-9.
  20. Berchuck A, Rubin SC, Hoskins WJ, Saigo PE, Pierce VK, Lewis JL. Treatment of endometrial stromal tumors. Gynecol Oncol 1990; 36(1): 60-5.
  21. Weitmann HD, Knocke TH, Kucera H, Pötter R. Radiation therapy in the Treatment of endometrial stromal sarcoma. Int J Radiat Oncol Biol Phys 2001; 49(3): 739-48.